In addition, SGLT-2 inhibitors have shown benefit in patients with both HFrEF and HFpEF independently of diabetes status, which opens exciting possibilities for the use of these therapies in patients at risk for or with established CV or kidney disease without T2D
The best supplement is the one you actually remember to take
Sackmann-Sala L, Ding J, Frohman LA, Kopchick JJ
(Eli Lilly is developing an oral GLP-1 treatment, too, but doesnt anticipate FDA approval until Q2.) Navigate the healthcare industry Healthcare Brew covers pharmaceutical developments, health startups, the latest tech, and how it impacts hospitals and providers to keep administrators and providers informed
Digestive upset such as bloating, nausea, or cramping Headaches as the body adjusts to increased detox support Rare allergic reactions like skin flushing or rash These tend to be temporary and improve with hydration, food pairing, or dose adjustments